These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21794078)

  • 1. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.
    Liu XR; Cai Y; Cao X; Wei RC; Li HL; Zhou XM; Zhang KJ; Wu S; Qian QJ; Cheng B; Huang K; Liu XY
    J Cell Mol Med; 2012 Jun; 16(6):1298-309. PubMed ID: 21794078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
    Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer targeting gene-viro-therapy specific for liver cancer by α-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24.
    Cao X; Wei R; Liu X; Zeng Y; Huang H; Ding M; Zhang K; Liu XY
    Acta Biochim Biophys Sin (Shanghai); 2011 Oct; 43(10):813-21. PubMed ID: 21835849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
    Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
    Zhang KJ; Wang YG; Cao X; Zhong SY; Wei RC; Wu YM; Yue XT; Li GC; Liu XY
    Hum Gene Ther; 2009 Aug; 20(8):818-30. PubMed ID: 19320563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.
    Zhao L; Gu J; Dong A; Zhang Y; Zhong L; He L; Wang Y; Zhang J; Zhang Z; Huiwang J; Qian Q; Qian C; Liu X
    Hum Gene Ther; 2005 Jul; 16(7):845-58. PubMed ID: 16000066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
    Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
    Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.
    Liu C; Sun B; An N; Tan W; Cao L; Luo X; Yu Y; Feng F; Li B; Wu M; Su C; Jiang X
    Mol Oncol; 2011 Dec; 5(6):545-54. PubMed ID: 22032823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.
    Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction of an oncolytic adenovirus expressing small hairpin RNA and targeting the SATB1 gene].
    Mao LJ; Zheng JN; Li W; Wang JQ; Chen JC; Sun XQ
    Zhonghua Nan Ke Xue; 2010 Aug; 16(8):679-83. PubMed ID: 21090340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
    Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.